Zentalis

Zentalis :
Discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. Broad pipeline of potentially best-in-class oncology candidates, including ZN-c5, an oral selective estrogen receptor degrader for ER+/HER2- breast cancer, ZN-c3, a WEE1 inhibitor, ZN-d5, a BCL-2 inhibitor and ZN-e4, an EGFR inhibitor.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Middle Atlantic
Clinical Stage
Phase l or ll
Disease Space
Oncology
Listing
Public, USA
Market Cap
1B +
Website:
Profiles:
Address:
530 Seventh Avenue, Ste 2201
Corner of 39 St
New York, NY 10018
United States
Corner of 39 St
New York, NY 10018
United States
Presentation:
More info:
My account:
Company Participants at Solebury Trout CEO & Investor Ski Conference 2020
- Anthony Sun, CEO
- Melissa Epperly, CFO
Lead Programs
ZN-c5: Oral SERD
oral selective estrogen receptor degrader (SERD)
Indication | Phase |
---|---|
Breast Cancer | 1/2 |
ZN-c3: WEE1
oral inhibitor of WEE1
Indication | Phase |
---|---|
Solid Tumors | 1/2 |
ZN-d5: BCL-2
oral selective inhibitor of B-cell lymphoma 2 (BCL-2)
Indication | Phase |
---|---|
Hematologic Malignancies | IND |
ZN-e4: EGFR
oral, small molecule inhibitor of mutant epidermal growth factor receptor (EGFR)
Indication | Phase |
---|---|
NSCLC | 1/2 |
Top 10 Holders of Zentalis Pharmaceuticals, Inc.
Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
---|---|---|---|---|---|
Viking Global Investors LP | 10.99 | 3,943,284 | 170.43 | Stakes | 12/1/20 |
Matrix Capital Management Co. LP | 10.65 | 3,821,739 | 165.18 | 13F | 9/30/20 |
Fidelity Management & Research Co. LLC | 7.95 | 2,850,720 | 123.21 | 13F | 9/30/20 |
Tybourne Capital Management (HK) Ltd. | 7.43 | 2,664,409 | 115.16 | 13F | 9/30/20 |
Redmile Group LLC | 6.78 | 2,432,408 | 105.13 | 13F | 9/30/20 |
The Vanguard Group, Inc. | 6.52 | 2,340,316 | 101.15 | Funds | 12/31/20 |
Citadel Advisors LLC | 5.24 | 2,129,964 | 92.06 | Stakes | 4/3/20 |
Citadel LP | 4.71 | 1,689,634 | 73.03 | 13F | 9/30/20 |
PRIMECAP Management Co. | 3.85 | 1,382,750 | 59.76 | 13F | 9/30/20 |
Vanguard Group, Inc. (Subfiler) | 3.09 | 1,109,753 | 47.96 | 13F | 9/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.